Rui Jie Yichang Humanwell Pharmaceutical

Yichang Humanwell Pharmaceutical is a leading Chinese pharmaceutical company and a core subsidiary of Humanwell Healthcare Group, specializing in the central nervous system (CNS) therapeutic area. The company is the largest manufacturer of anesthetics and analgesics in China, holding a dominant market share in narcotic drugs such as fentanyl, sufentanil, and remifentanil. It operates advanced, GMP-certified manufacturing facilities and is recognized as a national production base for controlled substances. In addition to its extensive generic portfolio, Yichang Humanwell is actively developing innovative drugs, exemplified by the successful launch of the sedative remimazolam besylate. The company is increasingly focused on international expansion, seeking regulatory approvals in global markets to export its high-quality finished dosage forms and active pharmaceutical ingredients.